drugset / Trial / NCT06523621
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
Phase 2
Active not recruiting
1 enrolled
Wake Forest University Health Sciences
Atrium Health Levine Cancer Institute · collabBristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to evaluate if treatment with adjuvant nivolumab improves depth of response in patients with relapsed refractory multiple myeloma (RRMM) who achieve a less-than-ideal response to idecaptagene vicleucel.
Timeline
- Start
- 2025-02-28
- Primary completion
- 2026-03-21
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |